Skip to main content

Quipt Home Medical (QIPT) Gets a Buy from Stifel Nicolaus

Tipranks - Tipranks - Fri May 23, 2025

In a report released today, Justin Keywood from Stifel Nicolaus maintained a Buy rating on Quipt Home Medical (QIPT – Research Report), with a price target of C$6.70. The company’s shares closed yesterday at C$2.69.

Confident Investing Starts Here:

Keywood covers the Healthcare sector, focusing on stocks such as Knight Therapeutics, Andlauer Healthcare Group, and Cipher Pharmaceuticals. According to TipRanks, Keywood has an average return of -7.9% and a 37.55% success rate on recommended stocks.

In addition to Stifel Nicolaus, Quipt Home Medical also received a Buy from Benchmark Co.’s Bill Sutherland in a report issued on May 14. However, on May 20, Canaccord Genuity maintained a Hold rating on Quipt Home Medical (TSX: QIPT).

See Insiders’ Hot Stocks on TipRanks >>

QIPT market cap is currently C$130.3M and has a P/E ratio of -9.30.

Read More on TSE:QIPT:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).